Stock Track | WuXi AppTec Soars as Nomura Upgrades Outlook and Price Targets

Stock Track10-25

Shares of WuXi AppTec, a leading pharmaceutical services company in China, surged on Thursday, with the Hong Kong-listed stock climbing 6.51% and the Shanghai-traded shares rising 5.3%. The stock rallies came after Nomura, a prominent brokerage firm, raised its price targets for both listings and reaffirmed its "buy" rating on the company.

Nomura's bullish stance on WuXi AppTec was driven by improving sentiment and expectations of accelerating growth in the third quarter of 2024, particularly in the company's chemistry segment. The brokerage slightly lifted its revenue and earnings forecasts for fiscal years 2024 and 2025, anticipating that the robust growth in the chemistry business will offset potential softening in other segments.

The analyst report highlighted WuXi AppTec's strong position in the rapidly growing pharmaceutical outsourcing market in China, where the company provides a wide range of services, including drug discovery, development, and manufacturing. With its extensive expertise and state-of-the-art facilities, WuXi AppTec has become a trusted partner for both domestic and international pharmaceutical companies seeking to tap into the lucrative Chinese market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185029982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-25 19:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185029982","market":"us","top_or_hot":-1,"title":"Stock Track | WuXi AppTec Soars as Nomura Upgrades Outlook and Price Targets","media":"Stock Track","content":"<p>Shares of WuXi AppTec, a leading pharmaceutical services company in China, surged on Thursday, with the Hong Kong-listed stock climbing 6.51% and the Shanghai-traded shares rising 5.3%. The stock rallies came after Nomura, a prominent brokerage firm, raised its price targets for both listings and reaffirmed its \"buy\" rating on the company.</p>\n\n<p>Nomura's bullish stance on WuXi AppTec was driven by improving sentiment and expectations of accelerating growth in the third quarter of 2024, particularly in the company's chemistry segment. The brokerage slightly lifted its revenue and earnings forecasts for fiscal years 2024 and 2025, anticipating that the robust growth in the chemistry business will offset potential softening in other segments.</p>\n\n<p>The analyst report highlighted WuXi AppTec's strong position in the rapidly growing pharmaceutical outsourcing market in China, where the company provides a wide range of services, including drug discovery, development, and manufacturing. With its extensive expertise and state-of-the-art facilities, WuXi AppTec has become a trusted partner for both domestic and international pharmaceutical companies seeking to tap into the lucrative Chinese market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | WuXi AppTec Soars as Nomura Upgrades Outlook and Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | WuXi AppTec Soars as Nomura Upgrades Outlook and Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-25 19:50 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of WuXi AppTec, a leading pharmaceutical services company in China, surged on Thursday, with the Hong Kong-listed stock climbing 6.51% and the Shanghai-traded shares rising 5.3%. The stock ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"药明康德","start_time":0,"source_url":"","article_id":"1185029982","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185029982","pubTimestamp":1729857027,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of WuXi AppTec, a leading pharmaceutical services company in China, surged on Thursday, with the Hong Kong-listed stock climbing 6.51% and the Shanghai-traded shares rising 5.3%. The stock rallies came after Nomura, a prominent brokerage firm, raised its price targets for both listings and reaffirmed its \"buy\" rating on the company.Nomura's bullish stance on WuXi AppTec was driven by improving sentiment and expectations of accelerating growth in the third quarter of 2024, particularly in ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02359":"药明康德"},"translate_title":"野村证券上调前景和价格目标，药明康德股市飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":1},"content_text":"Shares of WuXi AppTec, a leading pharmaceutical services company in China, surged on Thursday, with the Hong Kong-listed stock climbing 6.51% and the Shanghai-traded shares rising 5.3%. The stock rallies came after Nomura, a prominent brokerage firm, raised its price targets for both listings and reaffirmed its \"buy\" rating on the company.\nNomura's bullish stance on WuXi AppTec was driven by improving sentiment and expectations of accelerating growth in the third quarter of 2024, particularly in the company's chemistry segment. The brokerage slightly lifted its revenue and earnings forecasts for fiscal years 2024 and 2025, anticipating that the robust growth in the chemistry business will offset potential softening in other segments.\nThe analyst report highlighted WuXi AppTec's strong position in the rapidly growing pharmaceutical outsourcing market in China, where the company provides a wide range of services, including drug discovery, development, and manufacturing. With its extensive expertise and state-of-the-art facilities, WuXi AppTec has become a trusted partner for both domestic and international pharmaceutical companies seeking to tap into the lucrative Chinese market.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185029982"}